341 related articles for article (PubMed ID: 22031240)
1. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease.
McBride JL; Pitzer MR; Boudreau RL; Dufour B; Hobbs T; Ojeda SR; Davidson BL
Mol Ther; 2011 Dec; 19(12):2152-62. PubMed ID: 22031240
[TBL] [Abstract][Full Text] [Related]
2. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.
Boudreau RL; McBride JL; Martins I; Shen S; Xing Y; Carter BJ; Davidson BL
Mol Ther; 2009 Jun; 17(6):1053-63. PubMed ID: 19240687
[TBL] [Abstract][Full Text] [Related]
3. AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease.
Miniarikova J; Zimmer V; Martier R; Brouwers CC; Pythoud C; Richetin K; Rey M; Lubelski J; Evers MM; van Deventer SJ; Petry H; Déglon N; Konstantinova P
Gene Ther; 2017 Oct; 24(10):630-639. PubMed ID: 28771234
[TBL] [Abstract][Full Text] [Related]
4. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum.
Grondin R; Kaytor MD; Ai Y; Nelson PT; Thakker DR; Heisel J; Weatherspoon MR; Blum JL; Burright EN; Zhang Z; Kaemmerer WF
Brain; 2012 Apr; 135(Pt 4):1197-209. PubMed ID: 22252996
[TBL] [Abstract][Full Text] [Related]
5. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.
Franich NR; Fitzsimons HL; Fong DM; Klugmann M; During MJ; Young D
Mol Ther; 2008 May; 16(5):947-56. PubMed ID: 18388917
[TBL] [Abstract][Full Text] [Related]
6. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease.
Stanek LM; Sardi SP; Mastis B; Richards AR; Treleaven CM; Taksir T; Misra K; Cheng SH; Shihabuddin LS
Hum Gene Ther; 2014 May; 25(5):461-74. PubMed ID: 24484067
[TBL] [Abstract][Full Text] [Related]
7. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.
Harper SQ; Staber PD; He X; Eliason SL; Martins IH; Mao Q; Yang L; Kotin RM; Paulson HL; Davidson BL
Proc Natl Acad Sci U S A; 2005 Apr; 102(16):5820-5. PubMed ID: 15811941
[TBL] [Abstract][Full Text] [Related]
8. Widespread suppression of huntingtin with convection-enhanced delivery of siRNA.
Stiles DK; Zhang Z; Ge P; Nelson B; Grondin R; Ai Y; Hardy P; Nelson PT; Guzaev AP; Butt MT; Charisse K; Kosovrasti V; Tchangov L; Meys M; Maier M; Nechev L; Manoharan M; Kaemmerer WF; Gwost D; Stewart GR; Gash DM; Sah DW
Exp Neurol; 2012 Jan; 233(1):463-71. PubMed ID: 22119622
[TBL] [Abstract][Full Text] [Related]
9. Sustained effects of nonallele-specific Huntingtin silencing.
Drouet V; Perrin V; Hassig R; Dufour N; Auregan G; Alves S; Bonvento G; Brouillet E; Luthi-Carter R; Hantraye P; Déglon N
Ann Neurol; 2009 Mar; 65(3):276-85. PubMed ID: 19334076
[TBL] [Abstract][Full Text] [Related]
10. A series of N-terminal epitope tagged Hdh knock-in alleles expressing normal and mutant huntingtin: their application to understanding the effect of increasing the length of normal Huntingtin's polyglutamine stretch on CAG140 mouse model pathogenesis.
Zheng S; Ghitani N; Blackburn JS; Liu JP; Zeitlin SO
Mol Brain; 2012 Aug; 5():28. PubMed ID: 22892315
[TBL] [Abstract][Full Text] [Related]
11. Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice.
Keeler AM; Sapp E; Chase K; Sottosanti E; Danielson E; Pfister E; Stoica L; DiFiglia M; Aronin N; Sena-Esteves M
J Huntingtons Dis; 2016 Oct; 5(3):239-248. PubMed ID: 27689620
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.
Gabery S; Sajjad MU; Hult S; Soylu R; Kirik D; Petersén Å
Eur J Neurosci; 2012 Sep; 36(6):2789-800. PubMed ID: 22731249
[TBL] [Abstract][Full Text] [Related]
13. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts.
van Bilsen PH; Jaspers L; Lombardi MS; Odekerken JC; Burright EN; Kaemmerer WF
Hum Gene Ther; 2008 Jul; 19(7):710-9. PubMed ID: 18549309
[TBL] [Abstract][Full Text] [Related]
14. Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin.
Olson SD; Kambal A; Pollock K; Mitchell GM; Stewart H; Kalomoiris S; Cary W; Nacey C; Pepper K; Nolta JA
Mol Cell Neurosci; 2012 Mar; 49(3):271-81. PubMed ID: 22198539
[TBL] [Abstract][Full Text] [Related]
15. Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism.
Hu J; Liu J; Corey DR
Chem Biol; 2010 Nov; 17(11):1183-8. PubMed ID: 21095568
[TBL] [Abstract][Full Text] [Related]
16. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease.
Caron NS; Southwell AL; Brouwers CC; Cengio LD; Xie Y; Black HF; Anderson LM; Ko S; Zhu X; van Deventer SJ; Evers MM; Konstantinova P; Hayden MR
Nucleic Acids Res; 2020 Jan; 48(1):36-54. PubMed ID: 31745548
[TBL] [Abstract][Full Text] [Related]
17. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
18. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA
Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346
[TBL] [Abstract][Full Text] [Related]
19. Recombinant Adeno Associated Viral (AAV) vector type 9 delivery of Ex1-Q138-mutant huntingtin in the rat striatum as a short-time model for in vivo studies in drug discovery.
Ceccarelli I; Fiengo P; Remelli R; Miragliotta V; Rossini L; Biotti I; Cappelli A; Petricca L; La Rosa S; Caricasole A; Pollio G; Scali C
Neurobiol Dis; 2016 Feb; 86():41-51. PubMed ID: 26626080
[TBL] [Abstract][Full Text] [Related]
20. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
